Inventor
Roland A. Newman
Inventor
San Diego, CA, US
Overview
Patents· 27 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes27%
C07KPeptides27%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations21%
C12NMicroorganisms or enzymes12%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests8%
G01NInvestigating or analysing materials by determining their chemical or physical properties5%
C12YEnzymes1%
PatentTitleYear
10,323,095Antibody-fynomer conjugates20197,744,877'Expression and use of anti-CD20 Antibodies'20107,452,534'Recombinant anti-CD4 antibodies for human therapy'20087,422,739'Anti-CD20 antibodies'20087,381,560'Expression and use of anti-CD20 antibodies'20087,338,658'Recombinant anti-CD4 antibodies for human therapy'20087,122,187'Treating autoimmune diseases with humanized anti-CD40L antibody'20067,074,406'Treating allergic diseases with humanized anti-CD40L antibody'20066,682,734'Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma'20046,506,383'Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies'20036,440,418'Methods of treating autoimmune diseases with gp39-specific antibodies'20026,399,061'Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma'20026,136,310'Recombinant anti-CD4 antibodies for human therapy'20006,001,358'Humanized antibodies to human gp39, compositions containing thereof'19995,955,364'Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof'19995,939,068'Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof'19995,866,125'Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof'19995,843,439'Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma'19985,840,298'Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof'19985,811,524'Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof'19985,776,456'Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma'19985,756,096'Recombinant antibodies for human therapy'19985,750,105'Recombinant antibodies for human therapy'19985,736,137'Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma'19985,693,780'Recombinant antibodies for human therapy'19975,681,722'Recombinant antibodies for human therapy'19975,658,570'Recombinant antibodies for human therapy'1997Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1997–2004Patents assigned to IDEC PHARMA CORP (18)· patent assignee history
1997–2019Based in San Diego, CA, US· patent location history
2006–2010Patents assigned to BIOGEN IDEC INC (7)· patent assignee history
2019Patents assigned to MITSUBISHI TANABE PHARMA CORP (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| IDEC PHARMA CORP | 18 | 1997–2004 |
| BIOGEN IDEC INC | 7 | 2006–2010 |
| MITSUBISHI TANABE PHARMA CORP | 1 | 2019 |
Locations
| Location | Patents | Span |
|---|---|---|
| San Diego, California, US | 27 | 1997–2019 |